| ID | 1144 |
| Name of the vaccine | Synflorix |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 weeks to 2 years |
| Description of the vaccine | 10-valent Pneumococcal polysaccharide conjugate vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2009 and 2011 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | Synflorix vaccine effectiveness was 97% against vaccine-type and 6A IPD and 71% against 19A IPD. |
| Vaccine formulation | Turbid white suspension |
| Dosage | Infants from 6 weeks to 6 months: Three dose primary series and a booster dose, Infants from 7 to 11 months : Two doses and third dose in second year, Children from 12 to 23 months: Two doses. |
| Mechanism of action | The carrier proteins (PD, TT and DT) provide T-cell help to B-cells to produce a boostable antibody response of high affinity to the polysaccharide antigens. |
| Route of administration | Intramuscular |
| Indications | Protects against invasive disease and acute otitis media caused by Streptococcus pneumoniae. |
| Export | Marketing-authorisation holder : GlaxoSmithKline Biologicals S.A. |
| Approval | WHO and European Medicines Agency |
| Adjuvant | Aluminium phosphate |
| Repurposing | For pneumococcal infections, acute otitis media. |
| Side effects of vaccine | Redness at the injection site, irritability, drowsiness, appetite lost, fever. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.who.int/immunization_standards/vaccine_quality/Synflorix_WHO_leaflet_EN_May_2011.pdf |
| Other name | NA |
| Additional Links | https://gskpro.com/en-ca/products/synflorix/Efficacydata/invasive-pneumococcal-disease/
|